Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.
about
Intensive therapies for mantle cell lymphoma: time for a disease-specific approach?The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS groupFirst-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from thDownregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivoMature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.Proteasome inhibitors in mantle cell lymphomaBortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.Monoclonal antibody therapy of leukaemias and lymphomas.Non-Hodgkin's lymphomas, version 4.2014.A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.Therapeutic options in mantle cell lymphoma.Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma.Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.Mantle cell lymphoma: state-of-the-art management and future perspective.Emerging agents for the treatment of mantle cell lymphoma.Current and emerging new treatment strategies for mantle cell lymphoma.Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group.Management of mantle cell lymphoma in the elderly: current and potential strategies.Current regimens and novel agents for mantle cell lymphoma.Prognosis and outcome of stem cell transplantation for mantle cell lymphoma.Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.Front-line treatment of mantle cell lymphoma.Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma.Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant.Thalidomide therapy induces response in relapsed mantle cell lymphoma.High dose cytarabine with rituximab is an effective first-line therapy for mantle cell lymphoma and produces ample stem cell harvest yields after multiple chemotherapy cycles.Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma.A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma.Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospectiveReduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience.Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: a large multicenter comparative study in patients with malignant lymphoma.Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.
P2860
Q24299054-17622709-D2B5-4097-9D37-854857EA6E39Q26772907-CDD5823B-4937-443F-ACDC-2B23EA353B38Q33388563-C3EC84E0-02AA-42FA-8F4B-A9DF285EE3F0Q33408270-CE1D6B90-3C55-4AFF-B9C3-2EE8C852E04AQ33890300-90BE338E-275D-466D-8C8B-5C248914BB30Q34505392-28499619-479F-4739-8460-A5938D25A045Q34603567-52C96B55-A8B8-4ADD-9379-EA5DE04A2176Q36028745-B00324BF-74F7-4311-B088-7AFB39646567Q36117384-6189FEBC-B3C6-4399-8BB3-F0722277F47FQ36239669-FBB8D038-E0CF-433A-B135-A62119C7EFE4Q36820885-B4DBDE58-DD98-4D1A-88C4-1C030E683705Q36862857-060B1E73-38AD-46A8-9AF9-3AFC2F7AA569Q37093669-7A111786-AE36-4401-A7DC-99874A9FAFA2Q37250153-F1A78B7A-A5C1-448C-891D-1E853A724AB0Q37534534-96569D49-93AD-4B53-AE3F-47E073110460Q37534547-F4913DB6-263E-443F-8C49-91C663A81BCFQ37622873-22C0CF3C-A760-407F-84BA-30EA1FEA29B2Q38055498-8A36C0FC-D9F3-4231-8569-1DCDC53EAA02Q38056761-BCA35D79-BCF4-47FB-A155-18CA2C98C54DQ38110232-0C3B4E34-3ED9-4FFD-8D1D-77E14F8E3101Q38157682-DA5CC348-CEF1-430E-AF9B-415ACEC1EA65Q38224186-95E82350-AFC1-4DF1-BBED-8055D28D93B4Q38532268-A55B13F9-BEDD-45F7-923C-F3B971828501Q38768069-1DBB003D-6665-4812-B013-A7F2536CB39DQ39044162-9B2B9885-C636-4DAF-AC4D-2DEBB7084552Q40202733-0E11C641-3688-4D1D-8987-0F7A76EA1A0DQ42629494-6BF9DC03-B401-4B09-BC3D-99FE5514D1E2Q44180625-671D68AD-7C2D-4097-925A-A7AA7AC260B5Q44531911-C1A8D485-6C88-4DA4-90FD-02C603C3C57FQ44582819-6F54CD97-83C2-415C-8DC2-B3FE396AC24DQ45842950-EE7AC636-B87D-47E8-80AD-B227505071EAQ45858592-E05A2DCA-EBCF-4085-BDF1-90BA1ACB5C29Q46060588-AC4EA80F-BACC-4E19-8025-47D1C6732AD7Q47564590-D1E9A3C9-32DC-4B08-AD8D-30C9EAD5FE5FQ53129637-EDDE6E33-572D-4C36-B877-6B5020F636FEQ53134173-A020B69E-2E4E-46EC-8AB8-A6196C1B36B1Q53178306-A9739440-A340-4572-91B9-4E060728B765Q53571230-52812A18-E06B-45CF-A4A9-6D01F89DBAABQ54231729-5D5647CC-170C-4695-8A76-09C3C27B13FCQ55513959-8EAD7231-5155-4155-9F87-F8074BA7EBC9
P2860
Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Sequential chemotherapy by CHO ...... lymphoma: a prospective study.
@en
Sequential chemotherapy by CHO ...... lymphoma: a prospective study.
@nl
type
label
Sequential chemotherapy by CHO ...... lymphoma: a prospective study.
@en
Sequential chemotherapy by CHO ...... lymphoma: a prospective study.
@nl
prefLabel
Sequential chemotherapy by CHO ...... lymphoma: a prospective study.
@en
Sequential chemotherapy by CHO ...... lymphoma: a prospective study.
@nl
P2093
P50
P356
P1433
P1476
Sequential chemotherapy by CHO ...... lymphoma: a prospective study
@en
P2093
Belanger C
Bouabdallah R
Djabarri M
P2888
P304
P356
10.1038/SJ.LEU.2402406
P577
2002-04-01T00:00:00Z
P5875
P6179
1034305970